Philippines

The Food and Drug Administration of the Philippines (FDA Philippines) is the primary regulatory authority responsible for the registration and oversight of health products, including pharmaceuticals, medical devices, diagnostics, and digital health solutions. It operates under the Department of Health (DOH) and is governed principally by Republic Act No. 9711 (FDA Act of 2009) and its Implementing Rules and Regulations, as well as Republic Act No. 3720 (Food, Drug and Devices, and Cosmetics Act). All health products must obtain a Certificate of Product Registration (CPR) or a License to Operate (LTO) before market entry. The registration process involves product classification, dossier evaluation, laboratory testing where required, and post-market surveillance obligations. Medical devices are further classified under FDA Circular No. 2020-036 into Classes A through D based on risk level, with higher-risk products subject to more rigorous review pathways.

Applicants must appoint a local authorized representative or distributor holding a valid LTO from FDA Philippines to submit and maintain product registrations. Dossier submissions are generally aligned with the ASEAN Common Technical Dossier (ACTD) format, consistent with the Philippines' commitments as an ASEAN member state, although the International Council for Harmonisation (ICH) Common Technical Document (CTD) format is increasingly accepted for pharmaceutical products. The FDA has undertaken significant modernization reforms in recent years, including the expansion of its online e-Portal submission system, streamlined fast-track and compassionate special permit pathways for priority health products, and enhanced harmonization with ASEAN regulatory frameworks. Mutual recognition of approvals from reference regulatory agencies, such as those of the United States, European Union, Japan, Canada, and Australia, may support expedited review under the ASEAN Harmonized Technical Requirements (AHTR) scheme.

Public procurement of health products in the Philippines is primarily centralized through the Department of Health (DOH), which manages national formulary listings, procurement planning, and distribution for government health facilities. The DOH works in conjunction with the Philippine Health Insurance Corporation (PhilHealth) for coverage and reimbursement decisions. Procurements are conducted in accordance with Republic Act No. 9184 (Government Procurement Reform Act) and its revised Implementing Rules and Regulations, with the Government Procurement Policy Board (GPPB) providing oversight. National procurement is facilitated through the Philippine International Trading Corporation (PITC) for bulk government purchases, and the Procurement Service of the Department of Budget and Management (PS-DBM) manages framework agreements for commonly used government supplies. Local Government Units (LGUs), particularly at the provincial and city levels, also conduct independent procurement for their respective health facilities, creating a decentralized secondary procurement layer that requires separate engagement strategies.

The private sector represents a substantial share of health product consumption in the Philippines, driven by out-of-pocket spending, private hospitals, and retail pharmacy chains. Key private distribution channels include major pharmaceutical wholesalers and established healthcare group networks. On the donor and multilateral funding side, international organizations such as UNICEF, the World Health Organization (WHO), the Global Fund to Fight AIDS, Tuberculosis and Malaria, USAID, and Gavi, the Vaccine Alliance actively support procurement of vaccines, diagnostics, and essential medicines for public health programs. Products procured through these channels typically require WHO prequalification or approval from a Stringent Regulatory Authority (SRA) as a prerequisite. The Philippine government has also introduced policies promoting local manufacturing, including Executive Order directives encouraging the domestic production of essential health products, and the DOH's Health Technology Assessment (HTA) process, managed by the Health Technology Assessment Council (HTAC), plays an increasingly important role in determining which products are included in benefit packages and procurement priority lists.